Compare Snowflake Inc (SNOW) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs TransMedics Group Inc — how do they compare? Snowflake Inc trades at $333.28 (market cap $116.01B), while TransMedics Group Inc trades at $87.62 (market cap $3.10B). The key difference: Snowflake Inc is far larger — about 37.4× TransMedics Group Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SNOW | TMDX | |
|---|---|---|
Market Cap | $116.01B | $3.10B |
Sector | Technology | Technology |
52-Week High | $334.70 | $150.42 |
52-Week Low | $121.11 | $61.99 |
Enterprise Value | $115.82B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Snowflake (SNOW) trades at $334.30, down 0.12% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong revenue growth to $3.63 billion in 2025, though net losses persist at -$1.29 billion. Recent news highlights AI platform enhancements and investor conferences, with earnings beats in the last three quarters.
Outlook remains growth-focused with AI adoption driving upside, but premium valuation (P/S 22.66) and sustained losses pose risks. Analyst consensus is bullish with an 80.77% buy rating, though competition and margin pressure require monitoring for stock investors.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
